1 day ago · The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

1 day ago · INDIANAPOLIS, Feb. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial guidance. "2024 was a ...

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

1 day ago · Thanks to impressive sales growth across multiple therapeutic areas in 2024, Eli Lilly seems to have assuaged investor concerns that its incretin drugs for diabetes and obesity were reaching a ...

2 days ago · Eli Lilly and Company announced its financial results for the fourth quarter of 2024 and detailed 2025 financial guidance.

1 day ago · On Thursday, Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings and provided 2025 guidance. The U.S. pharma giant reported ...

1 day ago · Eli Lilly stock rose Thursday despite lighter-than-expected sales of its weight-loss and diabetes drugs Zepbound and Mounjaro.

1 day ago · Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and pricing challenges loom. See more here.

2 days ago · Eli Lilly (LLY 3.35%) Q4 2024 Earnings Call Feb 06, 2025, 10:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Ladies and gentlemen, thank ...

Feb 6, 2024 · Revenue in Q4 2023 increased 28%. New Products(i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products(ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance.